New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Lisata Therapeutics, Inc. (LSTA) vs Radiopharm Theranostics Limited - Sponsored ADR (RADX)

Lisata Therapeutics, Inc. and Radiopharm Theranostics Limited - Sponsored ADR are both Biotechnology companies. Lisata Therapeutics, Inc. and Radiopharm Theranostics Limited - Sponsored ADR are of similar size ($10.6M and $9.8M). Across the 3 metrics below, Lisata Therapeutics, Inc. leads on 2 and Radiopharm Theranostics Limited - Sponsored ADR on 1.

Valuation

Metric LSTA RADX Biotechnology median
P/E n/m — 8.49
P/S 0.55 — 8.56
P/B 1.10 — 2.04
Price to free cash flow n/m — 23.84
EV/EBITDA 12.46 — 0.69
EV/Sales (18.03) — 8.00
Earnings yield (208.82%) — (35.81%)
Free cash flow yield (258.67%) — (25.41%)

Profitability

Metric LSTA RADX Biotechnology median
Gross margin 14.13% — 70.18%
Operating margin (398.56%) — 0.00%
Net margin (274.88%) — 0.00%
Free cash flow margin (137.78%) — 0.00%
Return on equity (138.59%) — (51.58%)
Return on assets (5.12%) — (45.91%)
Return on invested capital 0.00% — 0.00%

Growth

Metric LSTA RADX Biotechnology median
Revenue growth (TTM) 57.16% — 7.20%
EPS growth (last fiscal year) 20.42% (1.97%) 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric LSTA RADX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 14.09 1.16 4.79
Net debt to EBITDA 0.88 0.08 1.01

Dividend

Metric LSTA RADX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LSTA RADX Biotechnology median
Market cap 9.83m 10.57m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack